340B Omnibus Guidance Could Lead To Increased Drug Costs
New guidance from the U.S. Health Resources Services Administration clarifying certain definitions integral to the 340B Drug Pricing Program will significantly limit the number of patients eligible to receive 340B drugs, resulting...To view the full article, register now.
Already a subscriber? Click here to view full article